HOME >> MEDICINE >> NEWS
New rapid anthrax test developed through collaboration between Mayo Clinic and Roche Diagnostics. Test, which provides results in less than one hour, will be made available to United States laboratories

ROCHESTER, MINN./INDIANAPOLIS, IND. -- Mayo Clinic has developed a new DNA test to rapidly identify anthrax in human and environmental samples. Roche Diagnostics is making the test widely available to public health agencies, hospital laboratories and reference laboratories in the United States and other countries. The new test can identify the presence of anthrax in less than one hour instead of days.

"The first thing people want to know in a case of suspected exposure is whether the agent was in fact anthrax," says Franklin R. Cockerill, III, M.D., the Mayo Clinic microbiologist who led the development team. "Until now, local labs have been able to quickly determine the presence of a bacterium, but they cant tell whether it is anthrax or not. The current process to identify the presence of anthrax may take several days. The events of the last several weeks require as rapid a response as possible."

Roche plans to give regional and local laboratories the ability to perform rapid DNA testing, eliminating the waiting period currently required at most laboratories to identify anthrax. Thus, a larger number of laboratories will now be able to provide a rapid "yes" or "no" answer.

"This rapid identification will enable doctors to begin more timely treatment of patients who have been exposed to anthrax, and it will more quickly alleviate undue anxiety for people who havent been exposed," says Dr. Cockerill.

The Mayo Clinic team led by Dr. Cockerill developed the test using Roche's LightCycler instrument for polymerase chain reaction (PCR)-based assays. To make the test widely available, Roche significantly accelerated production of the reagents needed to run the assay.

"Making this test available in a very short time frame is our contribution to the fight against bioterrorism and is a direct outcome of the excellent cooperation between Roche and Mayo Clinic," says Martin Madaus, President and CEO of Roche Diagnostics Corporation.
'"/>

Contact: John Murphy
newsburea@mayo.edu
507-284-5005
Mayo Clinic
5-Nov-2001


Page: 1 2

Related medicine news :

1. Studies address issues of risk and survival in rapidly increasing GI cancers
2. Successful, rapid protein crystallization possible with technique developed by UCSD researcher
3. SARS outbreak in Beijing spread rapidly, was controlled fairly quickly
4. Sandia nanolaser may help extend life-spans by rapidly analyzing possible neuroprotectant drugs
5. Research reveals no benefit of rapid MRI over X-rays in patients with low back pain
6. Improved molecular beacons show promise for cancer detection, rapid viral diagnosis
7. UT Southwestern, Childrens Medical Center to test new rapid diagnostic equipment
8. Stroke: Journal of the American Heart Association moves to Web-based rapid access weekly publication
9. New research suggests rapid screening technique for macular degeneration
10. Some patients not seeking rapid heart attack care
11. New data shows rapid and sustained weight loss with Xenical

Post Your Comments:
(Date:5/30/2015)... The results of a 40+ year study ... potential to cause mesothelioma, regardless of the volume of ... the Surviving Mesothelioma website. , The study conducted ... Poland found that, among the 138 cases of mesothelioma ... all of them happened at plants that had, at ...
(Date:5/30/2015)... San Diego, CA (PRWEB) May 30, 2015 ... public is the lack of local healthcare options available. ... access to adequate healthcare. For those in rural areas ... those simply without health insurance or tired of paying ... announces new E-consults, connecting patients with licensed physicians via ...
(Date:5/30/2015)... 30, 2015 On Thursday, May ... Charles Simone and Dr. Evan Alley both of ... the Mesothelioma Experts’ series. The interview was part ... centers of excellence. Drs. Simone and Alley were ... Hesdorffer, with whom they discussed the mesothelioma program ...
(Date:5/30/2015)... May 30, 2015 Boston Scientific ... in punitive and compensatory damages to a transvaginal ... serious complications following implantation of the company’s Pinnacle ... rendered on May 28th in Delaware Superior Court, ... damages after the jury found that the implants ...
(Date:5/30/2015)... ProIntro Magnify contains 30 self-animating and minimalistic Titles including ... elegant opening title to any Final Cut Pro X ... layouts. ProIntro Magnify is created exclusively for Final Cut Pro ... Simply drag a preset into the FCPX timeline ... Inspector window then watch as ProIntro Magnify does the rest. ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2
(Date:5/30/2015)... N.J. , May 30, 2015  Eisai Inc. announced ... which showed that eribulin met the study,s primary endpoint evaluating ... adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma. ... Annual Meeting of the American Society of Clinical Oncology (ASCO) ... ASCO press conference on Saturday, May 30, and also in ...
(Date:5/30/2015)... IRVING, Tex. , May 30, 2015 /PRNewswire/ ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the utility of Caris Molecular ... in facilitating comparisons between tumors that share histological ... of the American Society of Clinical Oncology (ASCO) ...
(Date:5/29/2015)... OTTAWA , May 29, 2015 /CNW/ - Alliance ... Canada, is recalling the health product Galenic Health ... levels of lead for adolescents and children. The ... limits for children, but within acceptable limits for ... used to relieve digestive upset and disturbances. Alliance ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
Cached News: